Healthcare among top 10 fastest-growing companies

Two healthcare companies have made Inc.’s top 10 fastest-growing privately held companies in the U.S.

Healthcare became the largest employer in the U.S. in 2018, and it is expected to continue growing to hit more than 19% of U.S. GDP by 2027. However, some stakeholders have criticized the startup environment in healthcare, arguing new companies are sometimes set up to fail.

However, some innovators have pushed through to become major companies over the past several years.

Here are the healthcare companies that made the list:

#9: Providence Healthcare Management––Based in Cleveland, the company provides operational support to rehabilitation centers, assisted-living facilities and other healthcare providers in Ohio and Kentucky. The company has seen a major boost from the long-term care since 2017. Its 2018 revenue was reported at $225.9 million and has seen 12,565% growth over the last three years.

#6: Cano Health––With $271.8 million in 2018 revenue and three-year growth of 14,183%, Cano Health offers primary care plus other healthcare services across 36 clinics in Florida. The company, which started as a single primary care facility offering patients care for a flat rate of $30 per month, provides services to Floridians regardless of insurance status.

See the full list here.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.